Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Am I imagining things or is the new licensing agreement with Colorcon posted today not meaning contracts??
I think they received the second milestone payment in March.
The new licensing agreement is posted on APDN wesite
Shark, apparently a new Colorcon licensing agreement has just been posted.
Or it is an expansion of the existing agreement.
The RFIs on the fda site have gone up
About half the float traded so far
6 million shares traded in 30 minutes
Not unless they sign a lucrative contract. All kinds of agreements and MOU s.
But no contracts.
And the broken record continues.
Is this last press release Deja Vu? Isn’t this the same as the February news??
Someone explain the point?
Major dumping of shares on level II. Here we go again
No contracts:
Fertilizers
Cotton
Colorcon
Videojet
BLC leather
Designer goods
Yes, I’ve been a little pessimistic til now.
It really looks positive here for APDN. Whodathunk that Israel was so far ahead in medical marijuana development.
IMHO, APDN is in the midst of a comstock lode
It’s just that Environmental Groups have Koch Industries at the top of their lists of industrial polluters.
I think it’s better to avoid that one. Jmho
I surely hope that’s not true.
Some companies are just so evil, it’s better not to get involved.
Yep. It’s a whole bunch of social media including the Twit Universe full of Pot news.
Yes it is like a broken record for over 2 years.
First some no revenue tidbits.
Then weeks with no news.
Then doldrums.
Then another dismal quarter
No news from Colorcon or Videojet for over a year now.
Should those just be trashed with pima and fertilizers?
It is interesting. Tencel is partnered with GHCL:
“GHCL is working towards carbon neutrality for its entire textiles business by 2021. It is also actively using sustainable raw material in textiles-more sustainable cotton (BCI/organic/Supima), cellulosic fibres (Tencel Lyocell) and recycled PET fibres. In keeping with the circular economy, “
There are all kinds of fools.
In this case they and their money will not soon be parted.
Just take what you lost the last time you went to a casino.
Buy this stock. It’s not as dumb as roulette or buying a new car.
It looks like no one is ready to sell
Actually, I agree.
Someone without an agenda will have to decipher the last PR.
The cancer vaccines/ Cat-T cell research is complex.
RFID labeling to secure supply ?? Why not Runes?
That is so old school and easily faked.
Since Everledger is tied in, so is APDN.
That’s my thought.
It’s been historically lucrative at the ramp up stage when companies like this take necessary action to curb fraud.
Thx for that news release
Yes, and that system will provide no assurance to any concerned consumer.
It sounds more like a guaranteed tax cash flow for the Equalization Board.
I’m not surprised either that 30% of the MJ is toxic.
Poisonous pot found in 30% of samples from California stores. Some samples has cyanide from a fungicide spray.
Per NBC this morning.
The time and detail taken to explain every aspect of why APDN marking for Pharmaceuticals is a necessary step in the transition to stop fake drugs.
I don’t think Hayward would have posted that article on the website now unless he plans an announced development in pharma. Call it a hunch.
It could be this Judy Murray article. The text of this extensive article sure sounds like something major will be announced this week:
https://tabletscapsules.com/wp-content/uploads/pdf/tc_20181001_0033.pdf
Colorcon, Videojet, Theracan, ACG, Techmer, High end fashion and leather, Car T:
Any one of these with a single contract will lift this up.
And then we can stop the reverse split string
Found this by googling “ multiple reverse splits”:
“Unfortunately, reverse stock splits rarely seem to work. A Florida State study found that only 24% of reverse stock split stocks recover at least 20% of their market cap within 250 days of the reverse split. Since most of these reverse split stocks have endured heavy losses heading into the split, this low percentage of meaningful recovery paints a bleak picture for investors.
Typically, one or more reverse stock splits is the death knell for a stock. “
I think what Nasdaq is saying is that they will not consider a second reverse split in their review for continued listing.
There has to be other significant factors submitted to Nasdaq in the company’s reply for them to consider not delisting.
Perhaps that company had other extenuating circumstances or plans which were accepted prior to delisting.
I understand that. What I am saying is NASDAQ does not consider that as having complied with the continued listing requirement. Nasdaq doesn’t consider it but any company is free to do it.
Also, if Montgomery has been investing for 40+ years, he should be investing in secured bonds.
This very long term scenario is for youngsters wanting long term growth in a retirement account.
Montgomery’s little note sounded suspiciously like Hayward wrote it.
Shark, I was just told you can only do the reverse split once for Nasdaq compliance.
They won’t consider a second reverse split in considering pps compliance.
Montgomery’s main concern was dilution of shares .
Hayward has a paradox or catch-22 on his hands, however you look at it.
How will Hayward respond to Nasdaq on the share price?
I don’t think they will accept anything but a convincing plan to get the shares above $1.
Planning on issuing new shares would negate those plans. I don’t see a way out if the plans aren’t short term.
The paradox is that Montgomery sees this as very long term, which has to mean massive dilution.
After all, if there is no short term fix for the pps, what possible options are there.
Actually, the gross sales are better. I suspect it’s the continued growth in testing revenues.
One caveat on 1st Q. We don’t know when or how the millions in deferred revenue will be recognized.
Also the testing revenues have been growin Q over Q.
The important thing is t conference call.
Any developments in Videojet, Colorcon, ACG or government will send it higher.
So, what is the nature of this relationship.??
UL provides tags for machinery it has inspected. The tags say UL approved and we’ve all seen them.
These tags have been counterfeited per various reports.
If the APDN dna marker is not in the UL Tag, then what exactly is this good relationship??
I guess Sanjay would say the same for Colorcon, Techmer, Palmetto, Videojet, BLC. We can’t do anything with “good relationships “
Here it is(link didn’t work) we’ll see this week if any of this was true:
STONY BROOK N.Y., October, 24, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, has entered its FY2019 with strong momentum in the first month in textiles, food-based agriculture and through the LineaRx subsidiary. Textiles business expansion includes a shipment of taggant for the upland Delta cotton variety in the current 2018-2019 ginning season, two new pilots for the Company’s CertainT® system in synthetic textiles (following one additional customer pilot completed in September) and one new feasibility study for the tagging of a food-based agricultural commodity. LineaRx, the Company’s wholly-owned subsidiary focused on next-generation biotherapeutics, received a new order for PCR-produced DNA for biotherapeutic application(s).
“Our structure for managing people, processes and technologies supporting global cotton supply chains, from the U.S. and Australian cotton gins, to local customer sales and support in India and Europe, through to our testing labs in Stony Brook and Ahmedabad, India and our partnerships with IT platform companies, has been a necessary investment for our unique selling proposition in end-to-end supply chain traceability. This sets a foundation from which our other supply chain pilots can be initiated and completed more quickly,” stated Dr. James Hayward, president and CEO of Applied DNA.
Continued Dr. Hayward: “Our LineaRx opportunity looks strong, with steady inquiries incoming for DNA biotherapeutic products as the benefits of linear, PCR-produced DNA is highlighted in the media.”
Remember this? We’ll see this week if any of it was true:
http://files.constantcontact.com/a83c254f001/c85677f4-04b1-4f1b-b28d-90549db09ff4.jpg